Support of HIV Interventional Trials.
Abstract
Contract DAMD17-92C-2504, Support of HIV interventional trials, was initiated in October of 1992 and is administered by Dr. Owen S. Weislow of SRA Technologies, Inc.. This contract is intended to provide both research and development support of clinical studies in HIV antiviral chemotherapy, immunotherapy and immunoprophylaxis. A number of significant contributions to WRAIR's mission have been made by this contract during FY94. The most important of these is the extension of the 215 ARMS assay for genotypic resistance to a number of patients in a large-scale, nationwide clinical trial to assess the significance of this approach. A comparison of this genotypic approach with the classical phenotypic assays of drug resistance as described in this report will doubtedly demonstrate the usefulness of this assay for the clinical management of patient therapy. SRA has also developed an in vitro assay for the evaluation of antiviral gene constructs in established cell lines and is actively pursuing a system that will enhance the efficiency of transduction in PBMCs that will permit the study of primary isolates. Such a system will prove invaluable for the longterm culture and ex-vivo treatment of patient cells with antiviral genes. Finally, the efforts of this contract have resulted in the development of an improved system for the rapid and cost effective phenotypic analysis of resistance to antiviral drugs as described in the previous section.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 29, 1994
- Accession Number
- ADA292183
Entities
People
- Owen S. Weislow